AtomVie Global Radiopharma has opened a new radiopharmaceutical manufacturing facility in Hamilton, Ontario, following an investment of more than $160 million in a site the company says will expand production capacity by more than tenfold.
The 72,300-square-foot facility at 10 Aeropark Boulevard is designed to support radiopharmaceutical development and manufacturing from early-stage programs through commercial production. AtomVie described it as North America’s largest single-site contract development and manufacturing facility dedicated to radiopharmaceutical development.
The facility includes low- to high-throughput manufacturing capability and customizable space that can be dedicated to customers’ future needs. AtomVie said the purpose-built site is intended to help clients move programs through development, clinical manufacturing and commercial-scale production.
AtomVie is a spinout of the Centre for Probe Development and Commercialization, a McMaster University-based center established to advance radiopharmaceutical research, innovation and manufacturing in Canada.
The company said it is expanding its workforce as the facility moves toward full operations and is targeting more than 200 employees by the end of 2026. AtomVie did not disclose its current headcount or a timetable for reaching full operating capacity.
AtomVie said it has supported more than 70 clinical-development and technology-transfer programs over the past decade. The company also reported manufacturing more than 1,000 current good manufacturing practice batches and delivering more than 4,400 cGMP doses to patients in 28 countries across six continents, with a delivery success rate above 99%.
Bruno Paquin, AtomVie’s chief executive officer, said the new facility adds to the company’s scientific and manufacturing capabilities and is intended to help partners develop and commercialize radiopharmaceutical pipelines.
Kevin McNeill, chairman of AtomVie’s board, said the site expands the company’s operations to commercial scale and is designed to provide manufacturing reliability for radiopharmaceutical developers.
The opening event included government representatives, customers, partners and members of the radiopharmaceutical sector. AtomVie said the facility will support the development of precision cancer therapies for patients worldwide.